US EditionEli Lilly Signs $2.75 Billion Deal to Commercialize Insilico's AI-Discovered Drugs
Eli Lilly gains exclusive rights to AI-discovered oral drugs from Insilico, with $115 million upfront and up to $2.75 billion in royalties and milestones, accelerating global drug development.
- U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market.
- Insilico has developed at least 28 drugs using generative AI tools, with nearly half already at a clinical stage.
- The deal will give Insilico $115 million up front, with the remainder subject to regulatory and commercial milestones, along with royalties on future sales.
16 Articles
16 Articles
Eli Lilly leans into AI drug discovery with new licensing deal
US pharmaceutical giant Eli Lilly inked a $2.75 billion deal with a Hong Kong-listed biotech firm to create new medicines using AI.Insilico Medicine, which develops drugs in China and went public in December, says it has produced at least 28 medicines using generative AI tools, with nearly half at the clinical trial phase.The agreement points to China’s growing role in the global pharma sector: Lilly plans to invest $3 billion in the country ove…
US pharma giant Eli Lilly, Insilico Medicine secure deal worth $2.75 billion to bring AI-developed drugs to market
US pharmaceutical giant Eli Lilly has reached a deal worth $2.75 billion with Insilico Medicine. Under the agreement, Lilly will bring AI-developed drugs to the global market, while Insilico will receive $115 million upfront, with the remainder tied to regulatory approvals and commercial milestones
Coverage Details
Bias Distribution
- 58% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
